news, journals and articles from all over the world.
Liver transplant is considered the best treatment for liver cancer, but only available for patients with early-stage disease. Now a study led by Cedars-Sinai Cancer investigators has concluded that immunotherapy could make liver transplant an option for patients with later-stage cancer as well.
Physician-scientists from the Department of Urology at Cedars-Sinai will be attending the American Urological Association (AUA) Annual Meeting May 3-6 in San Antonio, Texas, and are available to discuss the latest research and innovations in urological care.
Using spatial analysis of tissue samples, Cedars-Sinai investigators have identified patterns that could predict whether patients with the most common type of ovarian cancer will experience early relapse after treatment.
When Elisa Schoenfeld, a child development specialist, learned she had tested positive for a BRCA gene mutation, she knew it raised her risk for breast and ovarian cancer. She and her daughter, Amira, who received similar genetic test results, visited the BRCA Ovarian Previvor Clinic at Cedars-Sinai.
In a new study, Cedars-Sinai Cancer investigators explored malpractice trends related to active surveillance as a treatment strategy across cancers. They found that to date, there has been no successful litigation related to active surveillance.
From artificial intelligence (AI) and data integration to natural language processing and statistics, the Cedars-Sinai Department of Computational Biomedicine is utilizing the latest technological advances to find solutions to some of the most complex healthcare issues.
In its latest global expansion, Cedars-Sinai International announced the opening of its new global office in Singapore.
Gastrointestinal cancers were once diagnosed primarily by location. A tumor in the liver was liver cancer, while one in the pancreas was pancreatic. The few chemotherapy treatments available affected the entire patient—sometimes causing difficult side effects.
The Department of Radiation Oncology at Cedars-Sinai Cancer has earned accreditation from the American Society for Radiation Oncology (ASTRO) Accreditation Program for Excellence.
Cedars-Sinai Cancer investigators have discovered a protein expressed on multiple myeloma cancer cells that drives disease growth and development. The new study found that blocking part of the protein’s unique signaling pathway stops myeloma growth in culture and in laboratory mice.
Amanda Butler and Isabella Bugatti, both just entering their 30s, were blindsided by a diagnosis that is on the rise among women their age: breast cancer.
During Breast Cancer Awareness Month, Cedars-Sinai Cancer experts are available to discuss an uptick in breast cancer among younger patients and the innovative ways the academic medical center is treating breast cancer in diverse Southern California communities and beyond.
A roundup of the latest medical discoveries and faculty news at Cedars-Sinai.
Cedars-Sinai has named Lali Medina-Kauwe, PhD, as the inaugural holder of the Carol Moss Foundation Chair in Medical Discovery.
Gynecologic oncologist Margaret Liang, MD, has joined the Cedars-Sinai Cancer Division of Gynecologic Oncology, providing care and clinical services for patients within the Department of Obstetrics and Gynecology. She also joins as director for the Gynecologic Oncology Fellowship Program.
New research from Cedars-Sinai Cancer investigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common cause of hereditary colorectal and endometrial cancers.
As men age, some of their cells lose the very thing that makes them biological males—the Y chromosome—and this loss hampers the body’s ability to fight cancer, according to new research from Cedars-Sinai Cancer.
Physicians at Cedars-Sinai Cancer are using a unique chemotherapy delivery system that offers hope to colorectal cancer patients whose disease has spread and who now have inoperable liver tumors. Cedars-Sinai is one of the few centers in the area to offer the therapy, called hepatic artery infusion (HAI) pump chemotherapy.
Physician-scientists from Cedars-Sinai Cancer are available for interviews to discuss the new draft recommendation by the U.S. Preventive Services Task Force that women at average risk for breast cancer should have a mammogram every other year beginning at age 40.
Vitamin D deficiency could be the reason African American men experience more aggressive prostate cancer at a younger age compared with European American men, new research from Cedars-Sinai Cancer suggests.
Investigators from Cedars-Sinai Cancer are collaborating on a streamlined clinical trial design in a study called Pragmatica-Lung.
Cedars-Sinai Cancer experts in the fields of pancreatic, gastrointestinal, skin and breast surgical oncology are available to share research findings and comment on the latest news coming out of the Society of Surgical Oncology 2023 International Conference on Surgical Cancer Care March 22-25 in Boston.
New insights into the effects of a hormonal treatment for transgender men, discovered by Cedars-Sinai investigators, could have implications for the treatment of breast cancer.
Nicholas Tatonetti, PhD, an expert in biomedical data science, has joined Cedars-Sinai as the vice chair of Computational Biomedicine and associate director for Computational Oncology at Cedars-Sinai Cancer.
Every day for six weeks, Neil Wank, a 26-year Los Angeles Police Department veteran who in December was diagnosed with an aggressive type of brain cancer called glioblastoma, was escorted down the long hallway leading to the Cedars-Sinai Cancer radiation therapy facility by his wife, Nikki, and 10 to 20 of his fellow officers.
In a large-scale nationwide study, investigators from Cedars-Sinai Cancer have confirmed that rates of pancreatic cancer are rising—and are rising faster among younger women, particularly Black women, than among men of the same age. Their work was published today in the peer-reviewed journal Gastroenterology.
The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recently recognized with two important hallmarks of quality: official accreditation for CAR T-cell therapy, and a third year in a row ranking among the top adult bone marrow transplant programs in the U.S.
Cedars-Sinai Cancer is taking on the country’s leading cause of cancer-related death with a new Lung Cancer Screening Program designed to reach more patients, simplify the screening process, and provide fast access to follow-up care.
Less than three years after joining the Cedars-Sinai Cancer faculty, hematologist-oncologists Justin Darrah, MD, and Akil Merchant, MD, are pioneering new research and bringing a new, comprehensive set of treatment options to patients in the recently established Lymphoma Program.
Physician-scientists from Cedars-Sinai Cancer will present research and are available for comment on breaking news throughout the American Society of Hematology Annual Meeting & Exposition taking place Dec. 10-13 in New Orleans.
Physician-scientists from Cedars-Sinai Cancer are available for comment on research being presented throughout the San Antonio Breast Cancer Symposium, taking place Dec. 6-10.
Jeannie Shen, MD, a fellowship-trained breast surgeon who is board-certified in general surgery, has been appointed medical director of the Breast Program at Huntington Hospital, an affiliate of Cedars-Sinai, and medical director of the International Health Program at Cedars-Sinai Cancer at Huntington Hospital.
Medical oncologist Tiffany Shaw, MD, has joined Cedars-Sinai Cancer as regional medical director for Supportive Care Medicine at Huntington Cancer Center, an affiliate of Cedars-Sinai Cancer.
Although breast cancer is more common in women, during October, Breast Cancer Awareness Month, experts from Cedars-Sinai Cancer are reminding men that they are at risk as well. One in every 100 breast cancers in the U.S. is diagnosed in a man, according to the Centers for Disease Control and Prevention.
Yuan Yuan, MD, PhD, a breast medical oncologist and physician scientist who specializes in triple-negative breast cancer and breast cancer immunotherapy, has joined Cedars-Sinai Cancer as director of Breast Oncology. Yuan will treat patients at Cedars-Sinai and at Huntington Cancer Center, an affiliate of Cedars-Sinai Cancer.
Cedars-Sinai Cancer is welcoming nine oncology specialists to its affiliate, Huntington Cancer Center. The cancer specialists will be based at Huntington’s Pasadena campus, making it easier for San Gabriel Valley residents to access Cedars-Sinai Cancer clinical trials and innovative treatment options.
Lali Medina-Kauwe, PhD, former co-leader of the Cancer Biology Program in Cedars-Sinai Cancer, has assumed a new role as associate director for Basic Research.
A Roundup of the Latest Medical Discoveries and Faculty News at Cedars-Sinai
People in Los Angeles County experience differences in cancer risk and survival depending on a variety of factors such as race/ethnicity, gender, sexual orientation, geographic location and socioeconomic status, according to a new study by investigators at Cedars-Sinai Cancer.
A Roundup of the Latest Medical Discoveries and Faculty News at Cedars-Sinai
Investigators from Cedars-Sinai Cancer have discovered that cancerous tumors called soft-tissue sarcomas produce a protein that switches immune cells from tumor-attacking to tumor-promoting. The study, published today in the peer-reviewed journal Cell Reports, could lead to improved treatments for soft-tissue sarcomas.
Marc Botnick, MD, a board-certified radiation oncologist with more than 20 years of experience managing all cancer types, has been named regional medical director for Radiation Oncology at Cedars-Sinai Cancer. His primary clinical practice site will be at Cedars-Sinai Tarzana Radiation Oncology, but he will work closely with physicians throughout the enterprise.
Holly Hammond faced one of the toughest-imaginable breast cancer scenarios. Her cancer was already advanced and had spread to her liver and lymph nodes when she discovered a tumor on her right breast. The tumor was negative for all of the markers that respond to targeted therapies for cancer treatment. She was also positive for the genes that mark her as especially prone to breast cancer.
Howard Sandler, MD, chair of the Department of Radiation Oncology at Cedars-Sinai Cancer, has been named president-elect of the American Society for Radiation Oncology (ASTRO). Sandler will begin his term as president-elect in October, followed by single-year terms as president, chair and then immediate past chair of the ASTRO Board.
A Roundup of the Latest Medical Discoveries and Faculty News at Cedars-Sinai
Experts from Cedars-Sinai Cancer are available to comment on the American Association for Cancer Research (AACR) Cancer Disparities Progress Report 2022, which will be released Wednesday, June 8, in a virtual congressional briefing. The report highlights the need to increase diversity in clinical trials and the cancer workforce, and it provides policy recommendations for addressing cancer disparities—all areas Cedars-Sinai Cancer is working to address.
Recently, Michael Wulfe, who is 61 and lives in West Hollywood, was on the phone with his sister, Stephanie Wulfe, in Dallas. They talk at least once a day, but that day, something wasn’t right. “I was talking, and then I didn’t have the words,” Wulfe said. “My sister immediately said, ‘Call Cedars-Sinai!’”
Results of a Phase II clinical trial led by Cedars-Sinai Cancer investigators indicate that an immunotherapy drug combination could extend the lives of those diagnosed with advanced non-small cell lung cancer, one of the most common forms of lung cancer. The research was presented today during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, with simultaneous publication in the peer-reviewed Journal of Clinical Oncology.
Patients newly diagnosed with cancer typically focus on one question, eclipsing all others: “What is my prognosis?”
Experts from Cedars-Sinai Cancer, ranked among the top 10 in the nation for cancer care, will present novel research and clinical advances throughout the 2022 annual meeting of the American Society of Clinical Oncology (ASCO), taking place in person and virtually June 3-7 in Chicago.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu